RPTX Valuation

Repare Therapeutics Inc

Add to Watchlist

Advanced Chart

1.720

+0.02(1.176%)1D

Overview
Forecast
Valuation
Earnings

RPTX Relative Valuation

RPTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RPTX is overvalued; if below, it's undervalued.

Historical Valuation

Repare Therapeutics Inc (RPTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.59 is considered Undervalued compared with the five-year average of -6.23. The fair price of Repare Therapeutics Inc (RPTX) is between 7.12 to 9.55 according to relative valuation methord. Compared to the current price of 1.70 USD , Repare Therapeutics Inc is Undervalued By 76.12%.

Relative Value

Fair Zone

7.12-9.55

Current Price：1.70

76.12%

Undervalued

0.00

Trailing

Forward

0.00

EV/EBITDA

Repare Therapeutics Inc. (RPTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -3.23. The thresholds are as follows: Strongly Undervalued below -11.51, Undervalued between -11.51 and -7.37, Fairly Valued between 0.91 and -7.37, Overvalued between 0.91 and 5.05, and Strongly Overvalued above 5.05. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.59

EV/EBIT

Repare Therapeutics Inc. (RPTX) has a current EV/EBIT of 0.59. The 5-year average EV/EBIT is -2.99. The thresholds are as follows: Strongly Undervalued below -11.17, Undervalued between -11.17 and -7.08, Fairly Valued between 1.10 and -7.08, Overvalued between 1.10 and 5.19, and Strongly Overvalued above 5.19. The current Forward EV/EBIT of 0.59 falls within the Historic Trend Line -Fairly Valued range.

3.59

Repare Therapeutics Inc. (RPTX) has a current PS of 3.59. The 5-year average PS is 88.64. The thresholds are as follows: Strongly Undervalued below -194.90, Undervalued between -194.90 and -53.13, Fairly Valued between 230.41 and -53.13, Overvalued between 230.41 and 372.17, and Strongly Overvalued above 372.17. The current Forward PS of 3.59 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Repare Therapeutics Inc. (RPTX) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.53. The thresholds are as follows: Strongly Undervalued below -48.43, Undervalued between -48.43 and -24.98, Fairly Valued between 21.91 and -24.98, Overvalued between 21.91 and 45.36, and Strongly Overvalued above 45.36. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Repare Therapeutics Inc. (RPTX) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.23. The thresholds are as follows: Strongly Undervalued below -59.12, Undervalued between -59.12 and -29.68, Fairly Valued between 29.22 and -29.68, Overvalued between 29.22 and 58.67, and Strongly Overvalued above 58.67. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Repare Therapeutics Inc (RPTX) has a current Price-to-Book (P/B) ratio of 0.66. Compared to its 3-year average P/B ratio of 1.13 , the current P/B ratio is approximately -41.32% higher. Relative to its 5-year average P/B ratio of 2.11, the current P/B ratio is about -68.61% higher. Repare Therapeutics Inc (RPTX) has a Forward Free Cash Flow (FCF) yield of approximately -144.04%. Compared to its 3-year average FCF yield of -61.34%, the current FCF yield is approximately 134.84% lower. Relative to its 5-year average FCF yield of -39.87% , the current FCF yield is about 261.32% lower.

0.66

P/B

Median3y

1.13

Median5y

2.11

-144.04

FCF Yield

Median3y

-61.34

Median5y

-39.87

Competitors Valuation Multiple

The average P/S ratio for RPTX's competitors is 52.01, providing a benchmark for relative valuation. Repare Therapeutics Inc Corp (RPTX) exhibits a P/S ratio of 3.59, which is -93.10% above the industry average. Given its robust revenue growth of -76.70%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RPTX.O

Repare Therapeutics Inc

Applied Therapeutics Inc

Performance Decomposition

Market capitalization of RPTX decreased by 50.58% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -3.24K to -6.70K.

The secondary factor is the Revenue Growth, contributed -76.70%to the performance.

Overall, the performance of RPTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-76.70%

1.07M → 250.00K

Revenue Growth

106.66%

-3.24K → -6.70K

Margin Expansion

-80.54%

-3.39 → -0.66

P/E Change

-50.58%